300966 共同药业
已收盘 02-27 15:00:00
资讯
新帖
简况
共同药业(300966.SZ)拟斥2000万元至3000万元实施回购
智通财经 · 02-21
共同药业(300966.SZ)拟斥2000万元至3000万元实施回购
共同药业最新公告:拟以2000万元至3000万元回购股份
证券之星 · 02-21
共同药业最新公告:拟以2000万元至3000万元回购股份
每周股票复盘:共同药业(300966)2024年度预计亏损2000万至2800万
证券之星 · 02-15
每周股票复盘:共同药业(300966)2024年度预计亏损2000万至2800万
【企业动态】共同药业新增1件法院诉讼,案由为与公司有关的纠纷案件执行
证券之星 · 02-07
【企业动态】共同药业新增1件法院诉讼,案由为与公司有关的纠纷案件执行
2月5日共同药业发布公告,股东减持39.47万股
证券之星 · 02-05
2月5日共同药业发布公告,股东减持39.47万股
共同药业(300966.SZ)遭股东丹创投减持39.47万股
智通财经 · 02-05
共同药业(300966.SZ)遭股东丹创投减持39.47万股
太平洋:给予共同药业增持评级,目标价位19.0元
证券之星 · 01-19
太平洋:给予共同药业增持评级,目标价位19.0元
共同药业:预计2024年全年归属净利润亏损2000万元至2800万元
证券之星 · 01-16
共同药业:预计2024年全年归属净利润亏损2000万元至2800万元
共同药业(300966.SZ)发预亏,预计2024年度净亏损2000万元-2800万元 同比由盈转亏
智通财经 · 01-16
共同药业(300966.SZ)发预亏,预计2024年度净亏损2000万元-2800万元 同比由盈转亏
共同药业:预计2024年亏损2000万元-2800万元
美港电讯 · 01-16
共同药业:预计2024年亏损2000万元-2800万元
共同药业(300966)11月4日主力资金净卖出747.50万元
证券之星 · 2024-11-05
共同药业(300966)11月4日主力资金净卖出747.50万元
共同药业(300966)11月1日主力资金净买入222.02万元
证券之星 · 2024-11-04
共同药业(300966)11月1日主力资金净买入222.02万元
共同药业(300966)2024年三季报简析:净利润减162.16%
证券之星 · 2024-10-24
共同药业(300966)2024年三季报简析:净利润减162.16%
图解共同药业三季报:第三季度单季净利润同比减270.23%
证券之星 · 2024-10-23
图解共同药业三季报:第三季度单季净利润同比减270.23%
共同药业(300966.SZ)发布前三季度业绩,净亏损1416.22万元
智通财经 · 2024-10-23
共同药业(300966.SZ)发布前三季度业绩,净亏损1416.22万元
共同药业(300966.SZ)股东丹创投、张欣拟合计减持不超3%股份
智通财经网 · 2024-09-27
共同药业(300966.SZ)股东丹创投、张欣拟合计减持不超3%股份
共同药业最新公告:控股股东、实际控制人的一致行动人拟减持不超过3%
证券之星 · 2024-09-27
共同药业最新公告:控股股东、实际控制人的一致行动人拟减持不超过3%
共同药业:控股股东、实际控制人的一致行动人丹创投、张欣计划减持公司股份不超过3,458,367股,即减持比例不超过公司当前总股本的3%。
美港电讯 · 2024-09-27
共同药业:控股股东、实际控制人的一致行动人丹创投、张欣计划减持公司股份不超过3,458,367股,即减持比例不超过公司当前总股本的3%。
共同药业最新公告:全资子公司共同生物收到3080万元政府补助
证券之星 · 2024-09-20
共同药业最新公告:全资子公司共同生物收到3080万元政府补助
共同药业:关于公司项目的信息,具体请以定期报告或临时性公告披露的信息为准
证券之星 · 2024-09-06
共同药业:关于公司项目的信息,具体请以定期报告或临时性公告披露的信息为准
加载更多
公司概况
公司名称:
湖北共同药业股份有限公司
所属行业:
医药制造业
上市日期:
2021-04-09
主营业务:
湖北共同药业股份有限公司的主营业务为甾体药物起始物料和中间体的研发、生产及销售,主要产品为甾体药物生产所需的起始物料和中间体。公司自成立以来专注于主营业务发展和科技创新,获得了各级政府及主管部门的认可和奖励。公司被认定为“湖北省植物甾醇工程技术研究中心”、“湖北省甾体药物及中间体工程研究中心”和“院士(专家)工作站”;并获得“省科技进步奖二等奖”、“科技型中小企业创新奖”和“发展工业经济优秀单位”等荣誉,凭借“利用植物甾醇发酵生产雄烯二酮新工艺”获得了中国生产力促进中心协会颁布的“中国好技术”称号。
发行价格:
8.24
{"stockData":{"symbol":"300966","market":"SZ","secType":"STK","nameCN":"共同药业","latestPrice":17.2,"timestamp":1740639837000,"preClose":17.15,"halted":0,"volume":2936800,"delay":0,"changeRate":0.0029,"floatShares":76665000,"shares":114999999,"eps":-0.121,"marketStatus":"已收盘","change":0.05,"latestTime":"02-27 15:00:00","open":17.16,"high":17.5,"low":16.82,"amount":50398900,"amplitude":0.0397,"askPrice":17.2,"askSize":20,"bidPrice":17.19,"bidSize":140,"shortable":0,"etf":0,"ttmEps":-0.121,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1740706200000},"marketStatusCode":5,"adr":0,"adjPreClose":17.15,"symbolType":"stock","openAndCloseTimeList":[[1740619800000,1740627000000],[1740632400000,1740639600000]],"highLimit":18.87,"lowLimit":15.43,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":115279416,"isCdr":false,"pbRate":2.35,"roa":"--","roe":"--","epsLYR":0.2,"committee":0.678883,"marketValue":1983000000,"turnoverRate":0.0383,"status":0,"floatMarketCap":1319000000},"requestUrl":"/m/hq/s/300966","defaultTab":"news","newsList":[{"id":"2513265468","title":"共同药业(300966.SZ)拟斥2000万元至3000万元实施回购","url":"https://stock-news.laohu8.com/highlight/detail?id=2513265468","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513265468?lang=zh_cn&edition=full","pubTime":"2025-02-21 19:11","pubTimestamp":1740136301,"startTime":"0","endTime":"0","summary":"智通财经APP讯,共同药业(300966.SZ)公告,公司拟使用自有资金及浦发银行提供的股票回购专项贷款资金实施回购公司股份方案。回购资金总额不低于人民币2000万元(含),不超过人民币3000万元(含);价格不超过人民币23.84元/股。回购期限自董事会审议通过回购股份方案之日起12个月内。目前公司已取得浦发银行出具的《贷款承诺函》,承诺为公司回购A股股份提供专项贷款支持,借款金额最高不超过人民币2700万元(含),借款期限为3年。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1252903.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300966"],"gpt_icon":0},{"id":"2513268780","title":"共同药业最新公告:拟以2000万元至3000万元回购股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2513268780","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513268780?lang=zh_cn&edition=full","pubTime":"2025-02-21 18:30","pubTimestamp":1740133831,"startTime":"0","endTime":"0","summary":"共同药业公告称,公司计划使用自有资金及金融机构提供的股票回购专项贷款资金,以集中竞价方式回购公司股份,回购价格不超过23.84元/股,资金总额不低于2,000万元(含),不超过3,000万元(含)。回购的股份将用于股权激励或员工持股计划,若未能在回购完成后三年内使用完毕,将依法注销。公司已取得浦发银行出具的《贷款承诺函》,承诺为公司回购A股股份提供最高不超过2,700万元(含)的专项贷款支持。以上内容为证券之星据公开信息整理,由智能算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025022100034783.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300966"],"gpt_icon":0},{"id":"2511626137","title":"每周股票复盘:共同药业(300966)2024年度预计亏损2000万至2800万","url":"https://stock-news.laohu8.com/highlight/detail?id=2511626137","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511626137?lang=zh_cn&edition=full","pubTime":"2025-02-15 12:25","pubTimestamp":1739593513,"startTime":"0","endTime":"0","summary":"截至2025年2月14日收盘,共同药业报收于16.63元,较上周的16.35元上涨1.71%。本周,共同药业2月11日盘中最高价报16.98元。2月10日盘中最低价报16.39元。共同药业当前最新总市值19.17亿元,在化学制药板块市值排名146/152,在两市A股市值排名4819/5130。本周关注点公司公告汇总:共同药业发布2024年度业绩预告,预计亏损2000万元至2800万元公司公告汇总共同药业发布了《2024年度业绩预告》,预计2024年度归属于上市公司股东的净利润亏损2000万元至2800万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025021500012290.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300966"],"gpt_icon":0},{"id":"2509772654","title":"【企业动态】共同药业新增1件法院诉讼,案由为与公司有关的纠纷案件执行","url":"https://stock-news.laohu8.com/highlight/detail?id=2509772654","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509772654?lang=zh_cn&edition=full","pubTime":"2025-02-08 05:58","pubTimestamp":1738965493,"startTime":"0","endTime":"0","summary":"证券之星消息,根据企查查数据显示,2月7日共同药业(300966)新增1件法院诉讼如下:案号:(2025)鄂0111执1026号法院:武汉市洪山区人民法院案由:与公司有关的纠纷案件执行申请人:苏某某被执行人:湖北共同药业股份有限公司案件类型:执行立案日期:2025年2月7日数据来源:企查查以上内容为证券之星据公开信息整理,由智能算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025020800054060.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300966","BK0239"],"gpt_icon":0},{"id":"2509095104","title":"2月5日共同药业发布公告,股东减持39.47万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2509095104","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509095104?lang=zh_cn&edition=full","pubTime":"2025-02-05 19:01","pubTimestamp":1738753278,"startTime":"0","endTime":"0","summary":"证券之星消息,2月5日共同药业发布公告《共同药业:关于控股股东、实际控制人的一致行动人减持计划期限届满暨减持结果的公告》,其股东丹江口市共同创新投资合伙企业(有限合伙)于2024年10月28日至2025年1月27日间合计减持39.47万股,占公司目前总股本的0.3424%,变动期间该股股价下跌21.51%,截止1月27日收盘报15.4元。股东增减持详情见下表:根据共同药业2024年三季报公布的十大股东详情如下:以上内容为证券之星据公开信息整理,由智能算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025020500029199.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300966"],"gpt_icon":0},{"id":"2509140598","title":"共同药业(300966.SZ)遭股东丹创投减持39.47万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2509140598","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509140598?lang=zh_cn&edition=full","pubTime":"2025-02-05 18:32","pubTimestamp":1738751560,"startTime":"0","endTime":"0","summary":"智通财经APP讯,共同药业(300966.SZ)公告,公司收到丹创投、张欣出具的《关于股份减持计划期限届满的告知函》,丹创投减持39.47万股,张欣未减持。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1246136.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300966"],"gpt_icon":0},{"id":"2504463499","title":"太平洋:给予共同药业增持评级,目标价位19.0元","url":"https://stock-news.laohu8.com/highlight/detail?id=2504463499","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504463499?lang=zh_cn&edition=full","pubTime":"2025-01-19 19:05","pubTimestamp":1737284717,"startTime":"0","endTime":"0","summary":"太平洋证券股份有限公司周豫,乔露阳近期对共同药业进行研究并发布了研究报告《Q4业绩符合市场预期,利润端短暂承压》,本报告对共同药业给出增持评级,认为其目标价位为19.00元,当前股价为15.45元,预期上涨幅度为22.98%。最新盈利预测明细如下:该股最近90天内共有1家机构给出评级,增持评级1家。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025011900001727.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300966","601099"],"gpt_icon":0},{"id":"2503966309","title":"共同药业:预计2024年全年归属净利润亏损2000万元至2800万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2503966309","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503966309?lang=zh_cn&edition=full","pubTime":"2025-01-16 18:02","pubTimestamp":1737021757,"startTime":"0","endTime":"0","summary":"证券之星消息,共同药业发布业绩预告,预计2024年全年归属净利润亏损2000万元至2800万元。共同药业2024年三季报显示,公司主营收入3.65亿元,同比下降5.1%;归母净利润-1416.22万元,同比下降162.16%;扣非净利润-1477.05万元,同比下降190.91%;其中2024年第三季度,公司单季度主营收入1.32亿元,同比上升12.24%;单季度归母净利润-904.36万元,同比下降270.23%;单季度扣非净利润-984.36万元,同比下降399.98%;负债率61.76%,投资收益38.24万元,财务费用1347.09万元,毛利率14.23%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025011600031236.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300966"],"gpt_icon":0},{"id":"2503295036","title":"共同药业(300966.SZ)发预亏,预计2024年度净亏损2000万元-2800万元 同比由盈转亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2503295036","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503295036?lang=zh_cn&edition=full","pubTime":"2025-01-16 17:17","pubTimestamp":1737019068,"startTime":"0","endTime":"0","summary":"智通财经APP讯,共同药业 发布2024年度业绩预告,预计全年归属于上市公司股东净亏损2000万元-2800万元,同比由盈转亏。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1238716.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300966","BK0239"],"gpt_icon":0},{"id":"2503508229","title":"共同药业:预计2024年亏损2000万元-2800万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2503508229","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503508229?lang=zh_cn&edition=full","pubTime":"2025-01-16 17:14","pubTimestamp":1737018859,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["300966","BK0239"],"gpt_icon":0},{"id":"2481599658","title":"共同药业(300966)11月4日主力资金净卖出747.50万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2481599658","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481599658?lang=zh_cn&edition=full","pubTime":"2024-11-05 09:22","pubTimestamp":1730769724,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年11月4日收盘,共同药业报收于18.7元,下跌2.04%,换手率5.45%,成交量4.09万手,成交额7615.98万元。11月4日的资金流向数据方面,主力资金净流出747.5万元,占总成交额9.81%,游资资金净流入181.35万元,占总成交额2.38%,散户资金净流入566.15万元,占总成交额7.43%。近5日资金流向一览见下表:共同药业融资融券信息显示,融资方面,当日融资买入676.26万元,融资偿还653.19万元,融资净买入23.07万元,连续3日净买入累计542.12万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110500008143.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300966"],"gpt_icon":0},{"id":"2480317811","title":"共同药业(300966)11月1日主力资金净买入222.02万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2480317811","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480317811?lang=zh_cn&edition=full","pubTime":"2024-11-04 09:18","pubTimestamp":1730683096,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年11月1日收盘,共同药业报收于19.09元,上涨1.06%,换手率9.18%,成交量6.9万手,成交额1.3亿元。11月1日的资金流向数据方面,主力资金净流入222.02万元,占总成交额1.7%,游资资金净流入40.54万元,占总成交额0.31%,散户资金净流出262.56万元,占总成交额2.02%。近5日资金流向一览见下表:共同药业融资融券信息显示,融资方面,当日融资买入1731.05万元,融资偿还1434.89万元,融资净买入296.16万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110400002427.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300966","BK0239"],"gpt_icon":0},{"id":"2478697358","title":"共同药业(300966)2024年三季报简析:净利润减162.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2478697358","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478697358?lang=zh_cn&edition=full","pubTime":"2024-10-25 06:09","pubTimestamp":1729807773,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期共同药业发布2024年三季报。根据财报显示,共同药业净利润减162.16%。截至本报告期末,公司营业总收入3.65亿元,同比下降5.1%,归母净利润-1416.22万元,同比下降162.16%。按单季度数据看,第三季度营业总收入1.32亿元,同比上升12.24%,第三季度归母净利润-904.36万元,同比下降270.23%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102500005356.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300966"],"gpt_icon":0},{"id":"2477837045","title":"图解共同药业三季报:第三季度单季净利润同比减270.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2477837045","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477837045?lang=zh_cn&edition=full","pubTime":"2024-10-23 16:47","pubTimestamp":1729673251,"startTime":"0","endTime":"0","summary":"证券之星消息,共同药业2024年三季报显示,公司主营收入3.65亿元,同比下降5.1%;归母净利润-1416.22万元,同比下降162.16%;扣非净利润-1477.05万元,同比下降190.91%;其中2024年第三季度,公司单季度主营收入1.32亿元,同比上升12.24%;单季度归母净利润-904.36万元,同比下降270.23%;单季度扣非净利润-984.36万元,同比下降399.98%;负债率61.76%,投资收益38.24万元,财务费用1347.09万元,毛利率14.23%。财报数据概要请见下图:以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102300027183.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300966"],"gpt_icon":0},{"id":"2477372645","title":"共同药业(300966.SZ)发布前三季度业绩,净亏损1416.22万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2477372645","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477372645?lang=zh_cn&edition=full","pubTime":"2024-10-23 16:25","pubTimestamp":1729671947,"startTime":"0","endTime":"0","summary":"智通财经APP讯,共同药业(300966.SZ)发布2024年第三季度报告,公司前三季度营业收入3.65亿元,同比下降5.10%;归属于上市公司股东的净亏损1416.22万元;归属于上市公司股东的扣除非经常性损益的净亏损1477.05万元;基本每股亏损0.12元/股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1197980.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300966"],"gpt_icon":0},{"id":"2470084701","title":"共同药业(300966.SZ)股东丹创投、张欣拟合计减持不超3%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2470084701","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470084701?lang=zh_cn&edition=full","pubTime":"2024-09-27 19:32","pubTimestamp":1727436773,"startTime":"0","endTime":"0","summary":"智通财经APP讯,共同药业(300966.SZ)公告,公司近日收到控股股东、实际控制人的一致行动人丹江口市共同创新投资合伙企业(有限合伙)(简称“丹创投”)、张欣出具的《关于股份减持计划的告知函》,丹创投、张欣计划以集中竞价交易方式或大宗交易方式减持公司股份不超过345.84万股(即减持比例不超过公司当前总股本的3%)。更多港股重磅资讯,下载智通财经app更多港股及海外理财资讯,请点击www.zhitongcaijing.com(搜索“智通财经”);欲加入智通港股投资群,请加智通客服微信(ztcjkf)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1188379.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1258","BK1555","BK0239","00410","300966","BK1229"],"gpt_icon":0},{"id":"2470704394","title":"共同药业最新公告:控股股东、实际控制人的一致行动人拟减持不超过3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2470704394","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470704394?lang=zh_cn&edition=full","pubTime":"2024-09-27 19:30","pubTimestamp":1727436639,"startTime":"0","endTime":"0","summary":"共同药业公告,公司控股股东、实际控制人的一致行动人丹创投、张欣计划以集中竞价交易方式或大宗交易方式减持公司股份不超过345.84万股,即减持比例不超过公司当前总股本的3%。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024092700034997.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300966"],"gpt_icon":0},{"id":"2470701511","title":"共同药业:控股股东、实际控制人的一致行动人丹创投、张欣计划减持公司股份不超过3,458,367股,即减持比例不超过公司当前总股本的3%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2470701511","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470701511?lang=zh_cn&edition=full","pubTime":"2024-09-27 19:27","pubTimestamp":1727436430,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["300966","BK1555","00410","BK1229","BK1258","BK0239"],"gpt_icon":0},{"id":"2468561900","title":"共同药业最新公告:全资子公司共同生物收到3080万元政府补助","url":"https://stock-news.laohu8.com/highlight/detail?id=2468561900","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468561900?lang=zh_cn&edition=full","pubTime":"2024-09-20 16:50","pubTimestamp":1726822224,"startTime":"0","endTime":"0","summary":"共同药业公告,全资子公司共同生物近日收到与资产相关的政府补助资金3080万元,占公司2023年度经审计净资产的比例为3.23%。公司将与资产相关的政府补助确认为递延收益,在相关资产使用寿命内按照合理、系统的方法分期计入损益。具体会计处理以会计师事务所审计确认的结果为准。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024092000023952.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300966","BK0239"],"gpt_icon":0},{"id":"2465660109","title":"共同药业:关于公司项目的信息,具体请以定期报告或临时性公告披露的信息为准","url":"https://stock-news.laohu8.com/highlight/detail?id=2465660109","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2465660109?lang=zh_cn&edition=full","pubTime":"2024-09-06 19:03","pubTimestamp":1725620628,"startTime":"0","endTime":"0","summary":"证券之星消息,共同药业09月06日在投资者关系平台上答复投资者关心的问题。投资者:共同药业半年报未披露维生素D3项目进展的信息,能否做补充说明!","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024090600033609.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300966"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1740702907561,"stockEarnings":[{"period":"1week","weight":0.025},{"period":"1month","weight":0.1169},{"period":"3month","weight":-0.0777},{"period":"6month","weight":0.1544},{"period":"1year","weight":0.0759},{"period":"ytd","weight":0.0663}],"compareEarnings":[{"period":"1week","weight":0.0111},{"period":"1month","weight":0.0423},{"period":"3month","weight":0.0185},{"period":"6month","weight":0.192},{"period":"1year","weight":0.1454},{"period":"ytd","weight":0.0108}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"湖北共同药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"14201人(较上一季度减少7.27%)","perCapita":"5398股","listingDate":"2021-04-09","address":"湖北省襄阳市宜城市小河镇高坑一组","registeredCapital":"11527万元","survey":" 湖北共同药业股份有限公司的主营业务为甾体药物起始物料和中间体的研发、生产及销售,主要产品为甾体药物生产所需的起始物料和中间体。公司自成立以来专注于主营业务发展和科技创新,获得了各级政府及主管部门的认可和奖励。公司被认定为“湖北省植物甾醇工程技术研究中心”、“湖北省甾体药物及中间体工程研究中心”和“院士(专家)工作站”;并获得“省科技进步奖二等奖”、“科技型中小企业创新奖”和“发展工业经济优秀单位”等荣誉,凭借“利用植物甾醇发酵生产雄烯二酮新工艺”获得了中国生产力促进中心协会颁布的“中国好技术”称号。","listedPrice":8.24},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.31.2","shortVersion":"4.31.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"共同药业(300966)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供共同药业(300966)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"共同药业,300966,共同药业股票,共同药业股票老虎,共同药业股票老虎国际,共同药业行情,共同药业股票行情,共同药业股价,共同药业股市,共同药业股票价格,共同药业股票交易,共同药业股票购买,共同药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"共同药业(300966)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供共同药业(300966)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}